A blood test intended to detect colorectal cancer performed well in a clinical study, a step towards expanding options for screening the potentially deadly disease. 

Published in the New England Journal of Medicine Wednesday, the study found the test correctly detected colorectal cancer in 83% of people confirmed to have the disease who were at average risk and not experiencing symptoms. For 10% of people, it falsely indicated they might have colon cancer when the colonoscopy found nothing.

“The results of the study are a promising step toward developing more convenient tools to detect colorectal cancer early while it is more easily treated,” corresponding author Dr. William M. Grady, a gastroenterologist at Fred Hutchinson Cancer Center, said in a news release. “The test, which has an accuracy rate for colon cancer detection similar to stool tests used for early detection of cancer, could offer an alternative for patients who may otherwise decline current screening options.”

CBS News chief medical correspondent Dr. Jon LaPook, a gastroenterologist at NYU Langone Health, said this promises to help usher in an alternative to current screening tests, including colonoscopy, stool testing for blood and stool testing for genetic material.

“A blood test is attractive because it’s relatively easy to do and there’s no ‘ick factor’ that can keep people from doing home stool testing,” he said. “In the New England Journal study, the cell-free DNA blood test detected 83% of colon cancers but only 65% (11 of 17) of those in stage 1, which are statistically the most curable, and I await further research to help determine its role in colon cancer screening.”

The test has not been approved by the Food and Drug Administration and most insurers do not cover it, but it is already on sale in the U.S. for $895, according to the Associated Press. The maker of the test, Guardant Health, anticipates an FDA decision this year, the outlet reported.

Led and funded by Guardant Health, the findings come a multisite clinical trial of nearly 8,000 people ages 45 to 84, where Guardant’s Shield blood test was compared to colonoscopy, the current gold standard for colorectal cancer screening. 

“The gold standard for colon cancer screening is colonoscopy because it can detect colon cancer in its earliest, most treatable stages and it can find and remove precancerous polyps before they have a chance to turn into cancer,” LaPook said. 

While colorectal cancer is common and preventable with screening, only about 50% to 60% of people who are eligible for screening actually take those tests, Grady said. 

“Getting people to be screened for cancer works best when we offer them screening options and then let them choose what works best for them” he said.

The study comes as more Americans are getting colon cancer, and at younger ages.

Colorectal cancer, once the fourth-leading cause of cancer deaths for people younger than 50, has leaped up the list, becoming the leading cause for men and ranking second for women, according to a study published earlier this year.

Overall, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, according to the American Cancer Society. The organization anticipates 106,590 new cases of colon cancer in 2024.